Device is combination product.Device evaluated by mfr: the complaint device was not received for analysis.The manufacturing batch record review confirmed that the device met all material, assembly and performance specifications.The investigation conclusion is anticipated procedural complication as the event is due to a known physiological effect of the procedure noted within the directions for use, and/or device labeling.(b)(4).
|
(b)(6) study.It was reported that myocardial infarction and restenosis occurred.In (b)(6) 2013, the subject presented with stable angina (ccs classification: 2) and was referred for cardiac catheterization.Target lesion #1 was located in the proximal right coronary artery (rca) with 75% stenosis and was 10 mm long with a reference vessel diameter of 3.0 mm.Target lesion #1 was treated with pre-dilatation and placement of a 3.00 x 12 mm study stent.Residual stenosis was 0%.The subject was discharged on dual antiplatelet therapy.In (b)(6) 2018, the subject presented with complaints of chest pain.Cardiac enzymes were elevated consistent with spontaneous myocardial infarction.The subject was placed on medicated, hospitalized, and referred for cardiac catheterization.The subject was evaluated found to be a poor candidate for surgery so it was decided to perform staged percutaneous coronary intervention to the stenosis in rca and left main.The 80% stenosis in the distal portion of the previously placed study stent in the proximal rca was treated with pre dilatation and placement of a 2.25x15mm non-bsc drug eluting stent.Post procedure, the residual stenosis was 0% with timi 3 flow.The 90% stenosed left main coronary artery was treated with pre dilatation and placement of a 4.00x16mm synergy stent in the proximal left anterior descending artery extending back into the mid left main.Post dilatation, the residual stenosis was 0% with timi 3 flow.The subject was discharged in stable condition.
|